Nouvelle déclaration d'incident
No de la demande: 2009-2724
Numéro de référence du titulaire d'homologation: Prosar 1-18984658
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: UNITED STATES
État: TENNESSEE
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Phenothrin-based non-specific Ultraguard Flea/Tick Drops for Dogs
Liquide
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Inconnu
Professionnel de la santé
Dog / Chien
Pomeranian
1
Homme
5
9.7
lbs
Cutanée
Unknown / Inconnu
Unknown / Inconnu
Système
Persisted until death
Oui
Inconnu
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
1-18984658: A reporter (veterinarian) called on 06/29/2009 to report the exposure of a dog to a flea and tick product containing the active ingredient Phenothrin. According to the reporter, the product was applied to the dog on 06/28/2009. An unknown time following product application, the dog developed lethargy and had a seizure. The owner called the veterinarian who recommended bathing the dog and having it evaluated the following day. The morning of the report, the dog was weak and the owner bathed the dog to remove the product. On presentation to the reporter, the dog was weak, had pale mucous membranes, was dehydrated, hypothermic, having brief seizures, coughing and fainting. A complete blood count revealed a slightly elevated white blood cell count. Blood could not be obtained for a chemistry profile. The dog had been treated with dextrose, dexamethasone S.P., IV fluids, and was being warmed. X-rays of the chest were within normal limits. The dog's heartworm status was unknown. The reporter was advised that pyrethroid toxicity can manifest as seizures/tremors, but the other signs described are not consistent with product exposure. A recommendation was made to consider shock, heartworm disease, or other toxins as a cause for the signs. The methocarbamol dose was provided and the reporter was encouraged to continue symptomatic and supportive care while ruling out other causes for the signs. On follow up, the reporter stated that the dog developed pulmonary edema and died. The reporter was provided the company's necropsy program information. No further information was obtained.
Mort